bioAffinity Technologies (BIAF) Short-Term Debt repayments (2023 - 2026)
bioAffinity Technologies has reported Short-Term Debt repayments over the past 3 years, most recently at $41339.0 for Q1 2026.
- Quarterly Short-Term Debt repayments rose 6.2% to $41339.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $53134.0 through Mar 2026, down 74.38% year-over-year, with the annual reading at $251746.0 for FY2023, N/A changed from the prior year.
- Short-Term Debt repayments was $41339.0 for Q1 2026 at bioAffinity Technologies, up from -$101156.0 in the prior quarter.
- Over five years, Short-Term Debt repayments peaked at $126096.0 in Q2 2023 and troughed at -$101156.0 in Q3 2025.
- The 3-year median for Short-Term Debt repayments is $42334.0 (2023), against an average of $43554.3.
- The largest YoY upside for Short-Term Debt repayments was 6.2% in 2026 against a maximum downside of 6.2% in 2026.
- A 3-year view of Short-Term Debt repayments shows it stood at $42334.0 in 2023, then plummeted by 338.95% to -$101156.0 in 2025, then surged by 140.87% to $41339.0 in 2026.
- Per Business Quant, the three most recent readings for BIAF's Short-Term Debt repayments are $41339.0 (Q1 2026), -$101156.0 (Q3 2025), and $74024.0 (Q2 2025).